These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 35582294)

  • 21. Beneficial effects resulting from oral administration of
    Souza ELS; Campos CLV; Reis DC; Cassali GD; Generoso SV; Cardoso VN; Azevedo V; Medeiros JD; Fernandes GR; Nicoli JR; Martins FS
    Benef Microbes; 2020 Dec; 11(8):779-790. PubMed ID: 33191778
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can Lactobacillus acidophilus improve minimal hepatic encephalopathy? A neurometabolite study using magnetic resonance spectroscopy.
    Ziada DH; Soliman HH; El Yamany SA; Hamisa MF; Hasan AM
    Arab J Gastroenterol; 2013 Sep; 14(3):116-22. PubMed ID: 24206740
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy.
    Kimer N; Krag A; Gluud LL
    Patient Prefer Adherence; 2014; 8():331-8. PubMed ID: 24672227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial.
    Lunia MK; Sharma BC; Sharma P; Sachdeva S; Srivastava S
    Clin Gastroenterol Hepatol; 2014 Jun; 12(6):1003-8.e1. PubMed ID: 24246768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibacterial MccM as the Major Microcin in
    Ma Y; Fu W; Hong B; Wang X; Jiang S; Wang J
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of rifaximin and lactulose treatments to chronic hepatic encephalopathy rats: An [
    Kong X; Luo S; Wu SY; Zhang J; Yang GF; Lu GM; Zhang LJ
    Brain Behav; 2024 Jul; 14(7):e3621. PubMed ID: 38970239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis.
    Irimia R; Trifan A
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1021-7. PubMed ID: 23700882
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Linkage of gut microbiome with cognition in hepatic encephalopathy.
    Bajaj JS; Ridlon JM; Hylemon PB; Thacker LR; Heuman DM; Smith S; Sikaroodi M; Gillevet PM
    Am J Physiol Gastrointest Liver Physiol; 2012 Jan; 302(1):G168-75. PubMed ID: 21940902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Probiotic
    Shi J; Ma D; Gao S; Long F; Wang X; Pu X; Cannon RD; Han TL
    Front Microbiol; 2023; 14():1219763. PubMed ID: 37649633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preventive effects of Escherichia coli strain Nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis.
    Schultz M; Strauch UG; Linde HJ; Watzl S; Obermeier F; Göttl C; Dunger N; Grunwald N; Schölmerich J; Rath HC
    Clin Diagn Lab Immunol; 2004 Mar; 11(2):372-8. PubMed ID: 15013990
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evolving concepts: the negative effect of minimal hepatic encephalopathy and role for prophylaxis in patients with cirrhosis.
    Prakash RK; Kanna S; Mullen KD
    Clin Ther; 2013 Sep; 35(9):1458-73. PubMed ID: 23972578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetically engineered E. coli Nissle attenuates hyperammonemia and prevents memory impairment in bile-duct ligated rats.
    Ochoa-Sanchez R; Oliveira MM; Tremblay M; Petrazzo G; Pant A; Bosoi CR; Perreault M; Querbes W; Kurtz CB; Rose CF
    Liver Int; 2021 May; 41(5):1020-1032. PubMed ID: 33548108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gut microbiota: its role in hepatic encephalopathy.
    Rai R; Saraswat VA; Dhiman RK
    J Clin Exp Hepatol; 2015 Mar; 5(Suppl 1):S29-36. PubMed ID: 26041954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of microbiota in hepatic encephalopathy.
    Bajaj JS
    Gut Microbes; 2014; 5(3):397-403. PubMed ID: 24690956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Randomized Controlled Trial Comparing the Efficacy of a Combination of Rifaximin and Lactulose with Lactulose only in the Treatment of Overt Hepatic Encephalopathy.
    Hasan S; Datta S; Bhattacherjee S; Banik S; Saha S; Bandyopadhyay D
    J Assoc Physicians India; 2018 Jan; 66(1):32-6. PubMed ID: 30341842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of overt hepatic encephalopathy.
    Sharma P; Sharma BC
    J Clin Exp Hepatol; 2015 Mar; 5(Suppl 1):S82-7. PubMed ID: 26041964
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intestinal-borne dermatoses significantly improved by oral application of Escherichia coli Nissle 1917.
    Manzhalii E; Hornuss D; Stremmel W
    World J Gastroenterol; 2016 Jun; 22(23):5415-21. PubMed ID: 27340358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: a double-blind randomized placebo controlled clinical trial.
    Petersen AM; Mirsepasi H; Halkjær SI; Mortensen EM; Nordgaard-Lassen I; Krogfelt KA
    J Crohns Colitis; 2014 Nov; 8(11):1498-505. PubMed ID: 24972748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy.
    Agrawal A; Sharma BC; Sharma P; Sarin SK
    Am J Gastroenterol; 2012 Jul; 107(7):1043-50. PubMed ID: 22710579
    [TBL] [Abstract][Full Text] [Related]  

  • 40.  Minimal hepatic encephalopathy in cirrhosis- how long to treat?
    Goyal O; Sidhu SS; Kishore H
    Ann Hepatol; 2017 Jan-Feb 2017; 16(1):115-122. PubMed ID: 28051800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.